Natus Medical (NASDAQ:BABY) Cut to “Strong Sell” at BidaskClub

Natus Medical (NASDAQ:BABY) was downgraded by investment analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a note issued to investors on Saturday, January 6th.

Separately, Zacks Investment Research upgraded Natus Medical from a “sell” rating to a “hold” rating in a research note on Friday, September 22nd. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $46.50.

Natus Medical (NASDAQ:BABY) traded down $0.05 during trading hours on Friday, reaching $28.95. The company had a trading volume of 862,791 shares, compared to its average volume of 545,740. The firm has a market cap of $901.91, a PE ratio of -482.50 and a beta of 0.84. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.36 and a current ratio of 4.21. Natus Medical has a 1-year low of $28.40 and a 1-year high of $43.60.

Natus Medical (NASDAQ:BABY) last posted its quarterly earnings data on Wednesday, October 25th. The medical equipment provider reported $0.40 EPS for the quarter, topping the Zacks’ consensus estimate of $0.38 by $0.02. Natus Medical had a positive return on equity of 12.06% and a negative net margin of 0.62%. The firm had revenue of $122.60 million for the quarter, compared to analyst estimates of $122.41 million. During the same quarter last year, the company earned $0.39 EPS. The company’s revenue was up 34.9% on a year-over-year basis. equities research analysts predict that Natus Medical will post 1.64 earnings per share for the current fiscal year.

In related news, Director William M. Moore sold 5,000 shares of the firm’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $41.01, for a total transaction of $205,050.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Dong Chune Christopher Chung sold 12,642 shares of the firm’s stock in a transaction on Monday, November 6th. The shares were sold at an average price of $42.91, for a total value of $542,468.22. Following the sale, the vice president now directly owns 141,414 shares in the company, valued at approximately $6,068,074.74. The disclosure for this sale can be found here. Company insiders own 5.50% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BABY. Koch Industries Inc. boosted its holdings in shares of Natus Medical by 7,423.5% during the 2nd quarter. Koch Industries Inc. now owns 462,472 shares of the medical equipment provider’s stock valued at $450,000 after acquiring an additional 456,325 shares in the last quarter. Hillcrest Asset Management LLC acquired a new stake in shares of Natus Medical during the 3rd quarter valued at $8,966,000. Daruma Capital Management LLC boosted its holdings in shares of Natus Medical by 13.1% during the 2nd quarter. Daruma Capital Management LLC now owns 1,470,839 shares of the medical equipment provider’s stock valued at $54,862,000 after acquiring an additional 169,890 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Natus Medical by 10.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,552,938 shares of the medical equipment provider’s stock valued at $57,924,000 after acquiring an additional 151,372 shares in the last quarter. Finally, Prudential Financial Inc. lifted its holdings in Natus Medical by 162.0% during the 2nd quarter. Prudential Financial Inc. now owns 225,031 shares of the medical equipment provider’s stock worth $8,393,000 after buying an additional 139,130 shares during the period. 99.94% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Natus Medical (NASDAQ:BABY) Cut to “Strong Sell” at BidaskClub” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/13/natus-medical-baby-stock-rating-lowered-by-bidaskclub.html.

Natus Medical Company Profile

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply